• English
    • German

Diagnostics: mRNA-clusters show either healthy our unhealthy patterns

The need for personalised diagnostics

Why are some obese people healthy and others are not? Why have today already one third of type-2-diabetics normal weight or are even underweight, and why is this group growing? Why do some patients respond well to a treatment, while others don’t?  All these questions and many more still remain unanswered.

Treating metabolic diseases needs to dig deeper than looking for simple symptoms like elevated blood glucose or high blood pressure. In fact, metabolic diseases can be the result of a multitude of dysfunctions of the energy metabolism. Understanding a patient’s individual manifestations of his diseases lies at the bottom of effective and personalised medicine.

Our solution

mRNA-analysis of the subcutaneous adipose tissue (SAT) enables a completely new approach in diagnostics. Our cluster-analysis of mRNA-patterns enables us to identify unhealthy metabolic patterns and to better understand the individual patient and the causes of his pathology. Based on the results of this mRNA-analysis  we can assign a patient to a therapy-relevant subgroup for which optimal treatment and outcomes are known.

Our diagnostic tests encompass a wide range of treatments. They are currently in final stage for preparation for market-entry.


Our DiaBar tests for metabolic conditions which recommend bariatric surgery as a therapy-option for patients with type-2-diabetes and fatty liver conditions (NAFLD/NASH). The test will be ready to market by the end of 2024.


HepDia clarifies the patient’s stage of a fatty liver conditions (NAFLD/NASH) and the patient’s disposition for a progressing fibrosis. The test will be ready to market by the end of 2024.


DiaSquare gives a comprehensive view on patient-individual dysfunctions of the energy metabolism in connection with type-2-diabetes. It recommends optimal treatment choices and identifies optimal personalised therapy-protocols. The test will be ready to market in 2024.

Further Tests

Further tests are under development.